Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years-Reference-Cited by-同舟云学术

Duration of fracture prevention after zoledronate treatment in women with osteopenia: observational follow-up of a 6-year randomised controlled trial to 10 years

Published:2024-04 Issue:4 Volume:12 Page:247-256
ISSN:2213-8587
Container-title:The Lancet Diabetes & Endocrinology
language:en
Short-container-title:The Lancet Diabetes & Endocrinology

Author:

Reid Ian R^ORCID,Horne Anne M,Mihov Borislav,Bava Usha,Stewart Angela,Gamble Gregory D

Funder

Health Research Council of New Zealand

Publisher

Elsevier BV

Reference19 articles.

1. Performance of FRAX and FRAX-based treatment thresholds in women aged 40 years and older: the Manitoba BMD Registry;Crandall;J Bone Miner Res,2019

2. Bone mineral density thresholds for pharmacological intervention to prevent fractures;Siris;Arch Intern Med,2004

3. Fracture incidence and secular trends between 1989 and 2013 in a population based cohort: the Rotterdam Study;Trajanoska;Bone,2018

4. Fracture prevention with zoledronate in older women with osteopenia;Reid;N Engl J Med,2018

5. Effects of zoledronate on cancer, cardiac events, and mortality in osteopenic older women;Reid;J Bone Miner Res,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. 3D Printed Calcium Phosphate Physiochemically Dual-Regulating Pro-Osteogenesis and Antiosteolysis for Enhancing Bone Tissue Regeneration;ACS Applied Materials & Interfaces;2024-07-02

2. Advances in the study of plant-derived extracellular vesicles in the skeletal muscle system;Pharmacological Research;2024-06

3. Intermittent dosing of zoledronic acid based on bone turnover marker assessment reduces vertebral and non-vertebral fractures;JBMR Plus;2024-05-31

4. Optimising zoledronate treatment holiday duration without loss of fracture prevention;The Lancet Diabetes & Endocrinology;2024-04